Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations

Oncotarget

June 6, 2024
This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating EGFR-mutant non-small cell lung cancer. continue reading »

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy

News

June 5, 2024
PRESS RELEASE: On June 3, 2024, a new research paper was published in Oncotarget, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.” continue reading »

Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167

Oncotarget

May 30, 2024

The Importance of Integrated Therapies on Cancer: Silibinin, an Old and New Molecule

News

May 28, 2024
PRESS RELEASE: On May 23, 2024, a new review was published in Oncotarget, entitled, “The importance of integrated therapies on cancer: Silibinin, an old and new molecule.” continue reading »

Combating Doxorubicin-Resistant Acute Myeloid Leukemia

Oncotarget

May 23, 2024
In this new study, researchers examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorubicin-resistant acute myeloid leukemia cell lines. continue reading »